Companies › Encoded Therapeutics
1 active drug program in 3 registered trials: 3 Phase 1; Neurology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ETX101 AAV9-delivered gene therapy encoding engineered transcription factor (eTFSCN1A) to increas | Ion channels | Phase 1 | Dravet Syndrome | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05419492 | ETX101 | Phase 1 | Dravet Syndrome | Neurology | Jun 2028 |
| NCT06112275 | ETX101 | Phase 1 | Dravet Syndrome | Neurology | Sep 2030 |
| NCT06283212 | ETX101 | Phase 1 | Dravet Syndrome | Neurology | Oct 2030 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.